Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Hyperimmune milk peptides (HMP), derived from cows immunized with specific antigens, have been investigated for their potential role in managing Inflammatory Bowel Disorders (IBD), including Crohn's disease and ulcerative colitis. The scientific rationale centers on the immunomodulatory properties of immunoglobulins and other bioactive peptides present in hyperimmune milk, which may help regulate gut inflammation and modulate immune responses.

Several small clinical trials and animal studies provide preliminary support for their use. For example, a double-blind, placebo-controlled pilot study (Playford et al., 2007, Aliment Pharmacol Ther) found that colostrum-enriched milk from hyperimmunized cows reduced gut permeability and improved symptoms in patients with mild-to-moderate Crohn's disease. Some animal studies also suggest that HMP can modulate cytokine production and reduce intestinal inflammation.

However, the body of evidence remains limited. Most studies are small, short-term, or preclinical, and there is a lack of large, high-quality randomized controlled trials. Systematic reviews (e.g., Davison et al., 2014, Nutrition Journal) highlight the need for more robust research before HMP can be recommended as a standard therapy for IBD.

In summary, while there is some scientific investigation and plausible mechanisms suggesting HMP may be beneficial in IBD, the evidence supporting its use is weak to moderate and not yet sufficient for strong clinical recommendations.

More about Hyperimmune milk peptides
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Hyperimmune milk peptides

Products containing Hyperimmune milk peptides